IHM
ALNY icon

Iguana Healthcare Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Iguana Healthcare Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-25,000
Closed -$1.57M – 83
2016
Q1 		$1.57M Buy
+25,000
New +$1.66M 0.57% 47

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Iguana Healthcare Management's ALNY Position: Q4 2016 in Review

Iguana Healthcare Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 150,000 shares — an estimated $10.2M sold.

Iguana Healthcare Management first reported a position in ALNY in Q3 2015 and held it in 5 quarters. The position peaked at $10.2M in Q3 2016. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

  • Iguana Healthcare Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Iguana Healthcare Management sold 150,000 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $10.2M.
  • Iguana Healthcare Management first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • Iguana Healthcare Management's Alnylam Pharmaceuticals position peaked at $10.2M in Q3 2016.
  • 211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Iguana Healthcare Management's 13F filing for Q4 2016, filed 14 Feb 2017.